2QV0 Stock Overview
A clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Chemomab Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.89 |
| 52 Week High | US$1.26 |
| 52 Week Low | US$0.40 |
| Beta | 0.21 |
| 11 Month Change | -10.55% |
| 3 Month Change | 23.61% |
| 1 Year Change | n/a |
| 33 Year Change | -92.58% |
| 5 Year Change | n/a |
| Change since IPO | -93.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QV0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.5% | 1.7% | 1.6% |
| 1Y | n/a | -25.5% | -0.8% |
Return vs Industry: Insufficient data to determine how 2QV0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2QV0 performed against the German Market.
Price Volatility
| 2QV0 volatility | |
|---|---|
| 2QV0 Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2QV0's share price has been volatile over the past 3 months.
Volatility Over Time: 2QV0's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Adi George | www.chemomab.com |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. Fundamentals Summary
| 2QV0 fundamental statistics | |
|---|---|
| Market cap | €12.15m |
| Earnings (TTM) | -€17.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs 2QV0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QV0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.34m |
| Earnings | -US$19.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 2QV0 perform over the long term?
See historical performance and comparison